Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
NCT04114630 · Novartis Pharmaceuticals · PHASE3 · withdrawn · last registry update 2020-06-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No patients were enrolled and global prioritization of pipeline and research strategy” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCRL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-02Phase 3 first posted: Allergan, Atogepant (NCT04829747)
- 2021-03-18Phase 3 first posted: Pfizer, BHV-3500 (zavegepant) + Placebo (NCT04804033)
- 2021-03-10Results posted on the registry: Allergan, Ubrogepant + Erenumab (NCT04179474)
- 2021-03-09Results posted on the registry: Novartis Pharmaceuticals, Erenumab (NCT03333109)
- 2021-03-04Results posted on the registry: Amgen, Erenumab + Placebo (NCT03812224)
- 2021-02-08Phase 3 first posted: Pfizer, Rimegepant (PF-07899801) (NCT04743141)
- 2021-02-05Phase 3 first posted: Allergan, Atogepant 60 mg + Placebo (NCT04740827)
- 2020-12-28Phase 3 first posted: AbbVie, Atogepant 60 mg (NCT04686136)
- 2020-12-23Results posted on the registry: Pfizer, Rimegepant + Placebo (NCT03237845)
- 2020-12-23Results posted on the registry: Pfizer, Rimegepant + Placebo (NCT03235479)
- 2020-12-02Phase 3 first posted: Pfizer, Rimegepant/BHV3000 + Matching placebo (NCT04649242)
- 2020-10-05Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT04574362)
- 2020-09-30Phase 3 first posted: Pfizer, Zavegepant + Placebo (NCT04571060)
- 2020-09-03Results posted on the registry: Pfizer, Rimegepant + Placebo (NCT01430442)
- 2020-07-30Phase 3 first posted: AbbVie, Ubrogepant 100 mg + Placebo (NCT04492020)
- 2020-07-02Results posted on the registry: Pfizer, Rimegepant (NCT03266588)
- 2020-06-18Phase 3 first posted: AbbVie, Atogepant 60 mg (NCT04437433)
- 2020-05-29Phase 3 first posted: Pfizer, Zavegepant (BHV-3500) (NCT04408794)
- 2020-04-15Phase 3 first posted: Pfizer, Zavegepant (BHV-3500) + Placebo (NCT04346615)
- 2020-03-27Results posted on the registry: Pfizer, Rimegepant + Placebo (NCT03461757)
- 2019-08-28Results posted on the registry: Allergan, Ubrogepant + Placebo-matching Ubrogepant (NCT02873221)
- 2019-06-03Results posted on the registry: Amgen, Erenumab + Placebo (NCT02542605)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision